Most Recent
Bayer launches High Court appeal to revive Xarelto patents
High Court 2024-11-28 5:09 pm By Cindy Cameronne

Bayer has filed a High Court challenge to a decision that invalidated its patents for blockbuster blood thinner Xarelto, saying it would adversely affect drug research and development.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Bayer’s patents for blockbuster blood thinner Xarelto invalid: court
Intellectual Property 2024-10-23 11:45 pm By Sam Matthews

Bayer has lost its battle to protect top-selling blood thinner Xarelto from generic competition, with the Full Court finding two patents for the drug are invalid.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Aristocrat seeks High Court do-over on Lightning Link patents
Appeals 2024-10-15 11:15 pm By Cat Fredenburgh

Aristocrat has asked the High Court to rule once and for all on whether its popular Lightning Link game is patentable, after a differently comprised court was evenly split on the question.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Aristocrat gets another shot at Lightning Link patent after novel split High Court decision
Intellectual Property 2024-08-30 11:07 pm By Cindy Cameronne

A judge has allowed Aristocrat to appeal a judge’s rejection of its application to patent its Lightning Link poker machine, citing novel questions raised by an equally split High Court decision about the patentability of its invention.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Samsung Bioepis’ ‘scattergun approach’ dooms bid for R&D docs in fight over Pfizer’s Enbrel patent
Intellectual Property 2024-06-27 11:54 pm By Andy Sidler

A judge has rejected Samsung Bioepis’ bid to discover research and development documents from Pfizer as it seeks to invalidate the drug giant’s patent for its blockbuster autoimmune drug Enbrel, agreeing with Pfizer that it may be “no more than an exercise in fishing”.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Pfizer calls out ‘impermissible fishing expedition’ in fight over Enbrel biosimilar
Intellectual Property 2024-06-05 10:17 pm By Andy Sidler

Drug giant Pfizer has blasted Samsung Bioepis’ “fishing expedition” in its suit alleging infringement of the patent for its blockbuster arthritis drug Enbrel, telling the court the Korean biotech should not be allowed to dig for new grounds of invalidity.  

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Neurim’s claim for additional damages survives in Circadin patent case
Intellectual Property 2024-06-03 11:48 pm By Sam Matthews

A judge has upheld Neurim Pharmaceutical’s claim for additional damages against two generic drug companies found to have infringed its patent for insomnia drug Circadin, despite the company’s failure to comply with an earlier ruling.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Law firm loses challenge to Glaxo’s term extension for COPD patent
Intellectual Property 2024-05-29 10:05 pm By Cindy Cameronne

Drug giant Glaxo has succeeded in extending the term for a patent for a drug that treats chronic obstructive pulmonary disease and asthma, with a delegate rejecting arguments from law firm Banki Haddock Fiora that the application was incorrectly based on a patent that was no longer valid because of amendments.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

After 7 years of litigation, patent for blockbuster sleep drug Circadin found valid
Intellectual Property 2024-04-18 11:21 pm By Sam Matthews

After a seven-year legal battle, a court has upheld the validity of Neurim Pharmaceutical’s patent for insomnia drug Circadin and ruled two generic drug companies infringed the intellectual property.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Aristocrat’s 6-year battle to patent Lightning Link poker machine ends in defeat
Intellectual Property 2024-04-12 9:30 pm By Cindy Cameronne

A judge has ruled gaming giant Aristocrat Technologies cannot patent its Lightning Link electronic poker machine, after six High Court Justices split on whether the popular game was eligible for patent protection.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?